Synthetech Announces Date for Fourth Quarter and Full Year Fiscal 2010 Earnings Release and Conference Call

ALBANY, Ore., June 7 /PRNewswire-FirstCall/ -- Synthetech, Inc. (OTC Bulletin Board: NZYM) today announced it will issue fourth quarter and full year financial results before the opening of the market on Thursday, June 10, 2010. Synthetech's fourth quarter and fiscal year concluded on March 31, 2010. Following the release of its financial results, Synthetech will host a conference call at 1:30 p.m. PT. Dr. Gregory Hahn, President and CEO, along with Gary Weber, Vice President of Finance and CFO, will discuss results and be available to answer related questions.

The conference call can be accessed by dialing 877-524-1203 at 1:15 p.m. PT and entering code 413413. Replays of the audio only conference will be available after the call via the investor area of Synthetech's website at www.synthetech.com.

About Synthetech

Synthetech, Inc., based in Albany, Oregon, is a fine chemicals company specializing in organic synthesis, biocatalysis and chiral technologies. We develop and manufacture amino acid derivatives, specialty amino acids, peptide fragments and proprietary custom chiral intermediates and specialty resins, primarily for the pharmaceutical industry. Synthetech produces advanced pharmaceutical intermediates in accordance with Current Good Manufacturing Practices (cGMP) in compliance with U.S. Food and Drug Administration (FDA) regulations. Our products support the development and manufacture of therapeutic peptides and peptidomimetic (peptide-like) small molecule drugs from early stages of a customer's clinical development through market launch and into commercial production. Synthetech's products also support the production of chemically-based medical devices. Synthetech's domestic and international customer base includes major pharmaceutical, contract drug synthesis firms, emerging biotechnology (virtual pharmaceutical) and medical device companies. We also supply catalog quantities of specialty amino acids to research institutions, universities and drug discovery firms.

SOURCE Synthetech, Inc.